HDAC overexpression has been detected in a broad range of cancers and is often associated with poor outcomes and shorter survival, including gastric cancer, ovarian cancer, prostate cancer, and multiple myeloma, etc.19–21,40. Here, HDAC9 is linked to plasma cell myeloma.